Strategies for enhancing the efficacy of … of VIP Laburthe M, et al. Regul Pept....
Transcript of Strategies for enhancing the efficacy of … of VIP Laburthe M, et al. Regul Pept....
1
Strategies for enhancing the efficacy of immunotherapy
Ned Waller MD, PhD, FACP
2Winship Cancer Institute | Emory University
Cancer Immunity PrinciplesTumors express antigens recognized by immune cells • Aberrant expression of embryonic antigens.• Clonotypic neo-oncogenes (bcr/abl; B-cell idiotype). • Over-expression of low expression antigens on tumors.
Tumor Surveillance: immune system limits cancer• Tumors may be eliminated before clinically detected.• Tumor development represents failure of immunity due to lack of antigen-specific responses or immune
paralysis.• Patients with tumors may have tumor-specific memory T cells.
Augmenting immunity causes cancer regression• Cytokine therapy- activate and expand T cells and NK cells• Monoclonal antibodies- direct cytotoxicity or antibody-dependent cellular cytotoxicity (ADCC)• Vaccine with to induce and amplify T-cell responses• Immune check-point blockade to reverse anergy of T cells• Infusion of antigen-specific T cells, NK cells
3Winship Cancer Institute | Emory University
Vaccines
CellularTherapies
AntibodiesTo TumorAssociatedAntigens
Immunological Modalities to Treat Cancer
4Winship Cancer Institute | Emory UniversitySchreiber RD, et al. Science. 2011;331(6024):1565-1570.
Tumors that develop in an immuno-deficient host can be eliminated by a competent immune system
5Winship Cancer Institute | Emory University
Distinction between tumor-associated antigens and tumor-specific antigens• Tumor associated: anti-CD20- Rituximab FDA approved in 11/26/1997
targets normal B-cells and CD20+ B-cell malignancies.
• Tumor specific: Neo-antigens created by oncogeneicmutations/translocations in tumors, recognized by TILS- T cells extracted from the tumor microenvironment and expanded ex vivo.
6Winship Cancer Institute | Emory University
Mutation Density Varies Across Different Cancers
7Winship Cancer Institute | Emory University
• Driver mutations (red) cause an increase in the cell's fitness.
• Mutations in housekeeper genes (pink) decrease a cell's fitness.
• Passenger mutations (green) have no effect on fitness
• Mutator mutations (yellow) leads to an increase in the cell mutation rate.
Datta RS, et al. Evol Appl. 2013;6(1):20-33.
8Winship Cancer Institute | Emory University
Naïve CD8+ T-cellCD45RA+ CCR7+ CD62L+
Apoptotic or Necrotic Cancer Cell
Antigen Processing and presentation of peptides on MHC I
Activated Cytotoxic CD8+ T-cell CD45RO+ CD38+ CD57+
Antigen presentation by dendritic dell
Cytolysis of Cancer Cell
Immature dendritic cell: pptakeof antigen from cancer cell
What Happens at the Beginning of Immune Responses?
9Winship Cancer Institute | Emory University
Checkpoint Blockade and the Immunological Synapse
Nirschl CJ, et al. Clin Cancer Res. 2013;19(18):4917-4924.
10Winship Cancer Institute | Emory University
Inhibition of antigen-specific T cells by PDL1 expression on tumors
IFN-γ
Pardoll D. Medocographia. 2014;36(3): 274-284.
11Winship Cancer Institute | Emory University
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
McDermott DF, et al. J Clin Oncol. 2015;33(18):2013-2020.
12Winship Cancer Institute | Emory University
Long-term Survival of Patients with Renal Cell Cancer Treated with High-dose IL-2
Yang JC, et al. J Clin Oncol. 2006;24(35):5676-5583.
13Winship Cancer Institute | Emory University
Three Different Mechanisms of Cellular Immunotherapy
Brody J, et al. J Clin Oncol. 2011;29(14):1864-1875.
14Winship Cancer Institute | Emory University
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Melinda Bachini2016
Lympho-depleting ChemotherapyCytoxan & Fludarabine
Tumor-specificT cells
Treatment of a patient using adoptive cell therapy with TILs containing Vb22+ ERBB2IP mutation-reactive T cells
Tran E, et al. Science. 2014;344(6184):641-645. Koh S, et al. J Hepatol. 2014;61(5):1175-1177.
15Winship Cancer Institute | Emory UniversityTran E, et al. Science. 2014;344(6184):641-645.
Clinical Response and Persistence of Expanded T Cells in Vivo
16Winship Cancer Institute | Emory University
Chimeric Antigen Receptor (CAR) T Cell Therapy
Signal 1 activation (CD3ζ)Signal 2 co-stimulation
2nd gen 4-1BB or CD283rd gen 4-1BB + CD28
Jackson HJ, et al. Nat Rev Clin Oncol. 2016;13(6):370-383.
17Winship Cancer Institute | Emory University
Complete regression of DLBCL three months following CART therapy
18Winship Cancer Institute | Emory University
DLBCL CAR T study: 59% Response Rate Patients(N = 51)a
Best overall response (CR + PR) 59% (95% CI, 44.2-72.4)P < .0001
CR 43%PR 16%SD 12%PD 24%
Overall response rate (CR + PR) at 3 months 45%
CR 37%PR 8%
a The interim analysis was preplanned to include the first 50 patients treated with CTL019 and followed for at least 3 months or discontinued early.
CI, confidence interval; CR, complete remission; ORR, overall remission rate; PD, progressive disease; PR, partial remission; SD, stable disease.
19Winship Cancer Institute | Emory University
Duration of Response: 79% Relapse-free at 6 Months
Duration of Response for patients in CR/PR (n = 30)
• Median DOR not reached (median follow up, 6.4 months)• All responses at 3 months were ongoing at the time of cut-off
– No responding patients went on to SCT
• Median OS not reached (median follow-up, 2.8 months; max, 11.7 months)DOR, duration of response; OS, overall survival; SCT, stem cell transplant.
9152530 9 6 1 1 0
100
80
60
40
20
0
Time (months)
Prob
abili
ty o
f eve
nt fr
ee (%
)
40 1 2 3 5 6 7 8
Events, n = 4Patients still at riskn =
20Winship Cancer Institute | Emory University
A.
CD
27
CD28
Healthy Untreated DLBCL Heavily-treated DLBCL
B. C.
A.
Total cellsCD27-CD28-depleted CD27-CD28-
Sytox blue
C.
FSCASS
CA
FSCW
FSC
HSytox blue
SSC
A
CD3SS
CA
CD28
CD
27
CD28
CD
27
CD28
CD
27
Pre-sort
Post-sort
SSC
A
B.
22Winship Cancer Institute | Emory University
Vasoactive intestinal polypeptide induces tolerogenic dendritic cells that limit inflammation
Waller EK. Blood. 2006;107(9):3423-3424.
23Winship Cancer Institute | Emory UniversityGonzalez-Rey E, et al. Nat Rev Immunol. 2017;7(1):52-63.
24Winship Cancer Institute | Emory University
Structural model of VPAC1 receptor and docking of VIP
Laburthe M, et al. Regul Pept. 2002;108(2-3):165-173.
25Winship Cancer Institute | Emory University
CD8 T-cells in the graft mediate the anti-leukemia activity of VIPhyb
Li JM, et al. Cancer Res. 2016;76(23):6802-6815.
26Winship Cancer Institute | Emory University
VIPhyb-treatment increased novel TCR-beta clones compared with donor and GvHDrecipients
DonorT cells
2.5%Oligoclonal
GvHDT cells
26%Oligoclonal
GvLT cells
22%Oligoclonal
Li JM, et al. Cancer Res. 2016;76(23):6802-6815.
27Winship Cancer Institute | Emory University
Strategies for cancer immunotherapy• Improving the anti-cancer T cell repertoire
• Vaccination with tumor-specific antigens• BMT CTN1401 DC-myeloma fusions• Dr. Al-Kadhimi myeloma peptide vaccine, MDSC depletion• Selecting non-anergic Tn and Tcm T cells for expansion• Ex vivo immunization with tumor-micro-vesicles• Optimization of antigen-specific T cell manufacturing
• NK cell infusions with super-agonist IL15
• Bi-specific antibodies to target T cells to tumor
• Combining Vaccines and check-point blockade
• In vivo vaccination with chemo/XRT combined with check-point blockade, cytokines
28Winship Cancer Institute | Emory University
Evolution of Immuno-oncology
Tum
or S
peci
ficity
Year
Off-
targ
et e
ffect
s
1970 1980 1990 2000 2010 2020
29Winship Cancer Institute | Emory University
Ehrlich and Morgenroth 1900. Berliner Klinische Wochenschrift. 2:196-204.
Paul Ehrlich, father of the “magic bullet” concept of chemotherapy and immunotherapy
“For the sake of brevity, that combining group of the protoplasmic molecule to which the introduced group is anchored will hereafter be termed receptor”
Paul Ehrlich 1854-1915
30Winship Cancer Institute | Emory [email protected]